논문검색
Author Duk-Joo Lee, M.D.1, Ho-Suk Oh, M.D.3, Jung-Hye Choi, M.D.1, Young-Yeul Lee, M.D.1, In-Soon Kim, M.D.1 and Myung-Ju Ahn, M.D.2
Place of duty 1Department of Internal Medicine, College of Medicine, Hanyang University, 2Department of Internal Medicine, College of Medicine, Sungkyunkwan University, Seoul, 3Department of Internal Medicine, Gangneung Asan Hospital, Gangneung, Korea
Title Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line Therapy
Publicationinfo Cancer Res Treat 2006 Dec; 038(04): 201-205.
Key_word Oxaliplatin, 5-fluorouracil, Leucovorin, Colorectal neoplasms
Full-Text
Abstract Purpose: The purpose of the study was to assess the efficacy and safety of biweekly oxaliplatin in combination with leucovorin (LV)-modulated bolus plus infusion of 5-fluorouracil (5-FU) in patients with relapsed or metastatic colorectal cancer (CRC) as a second line therapy. Materials and Methods: Between November 2002 and October 2005, 26 patients with histologically confirmed relapsed or metastatic CRC were enrolled. All patients were previously treated with irinotecan-based combination chemotherapy. The chemotherapy regimen consisted of oxaliplatin 85 mg/m2 on day 1; LV 200 mg/m2 on days 1 and 2; and 5-FU 400 mg/m2 bolus IV with 600 mg/m2 with a 22-hour infusion on days 1 and 2 every 2 weeks. Results: The median age of the 26 patients was 50.5 years (range, 31∼72). Their metastatic sites included: the liver (42.3%), peritoneum (26.9%), lung (23.1%) and ovary (7.7%). Twenty five patients were evaluated for their response. Four patients achieved partial responses and 15 patients had stable disease. The overall response rate was 16% (95% confidence interval; 1.7∼30.3%). The median follow-up duration for the surviving patients was 7.4 months (range, 2.08∼21.2). Median overall survival (OS) and 1-year OS rates were 16.7 months and 63.9%, respectively. The most common hematological toxicities were: NCI grade I/II leucopenia (49.3%), grade I/II neutropenia (41%) and grade I/II anemia (65.2%). The main non-hematological toxicities were: grade I/II peripheral neuropathy (16.1% and 21.5%, respectively) and nausea/ vomiting (23.6%/18.5%). There was no life-threatening toxicity. Conclusion: The oxaliplatin, 5-FU and LV combination chemotherapy, scheduled as a biweekly protocol, was effective and well tolerated in the treatment of relapsed or metastatic colorectal cancer patients as second line chemotherapy. (Cancer Res Treat. 2006;38:201-205)
출판정보 대한암학회지 2006 Dec; 038(04): 201-205.